

A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer

Submission date 05/11/2007	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 05/11/2007	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 20/03/2019	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Mark N. Levine

Contact details

Ontario Clinical Oncology Group (OCOG)

711 Concession St

Hamilton, Ontario

Canada

L8V 1C3

-

mlevine@mcmaster.ca

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00304759

Protocol serial number

MCT-78776

Study information

Scientific Title

A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer

Acronym

PROFIT (PROstate Fractionated Irradiation Trial)

Study objectives

To determine whether a 4-week course of hypofractionated radiotherapy is as safe and effective as a standard 8-week course of radiotherapy for treatment of intermediate risk localised prostate cancer.

On 12/11/2008 this record was updated to include an amendment to the exclusion criteria and a change of sponsor. The initial sponsor was McMaster University (Canada) as this was where the Ontario Clinical Oncology Group (OCOG) was initially based, but this has now moved to the Henderson Research Centre. Please also note that at this time, Australia was added to the trial countries of recruitment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Research Ethics Board of University Health Network, Toronto, Ontario, Canada, 16/01/2006, ref: 05-849-C
2. Research Ethics Board of McMaster University, Hamilton, Ontario, Canada, 21/02/2006, ref: 06-44

Approval for the amendment to the exclusion criteria was gained by the UHN on 16/05/2008 and the Hamilton Health Sciences on 19/08/2008.

Primary study design

Interventional

Study design

Multicentre two-arm randomised parallel trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Prostate cancer

Interventions

Conformal external beam radiotherapy.

Standard arm: 78 Gy in 39 fractions over 7.8 weeks (5 days a week)

Investigational arm: 60 Gy in 20 fractions over 4 weeks (5 days a week)

The below contact is for scientific and public queries.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Biochemical (PSA) relapse-free rate at 5 years post treatment.

Key secondary outcome(s)

1. Biochemical-Clinical Failure (BCF)
2. All-cause mortality
3. Prostate cancer specific mortality
4. Treatment-related toxicity
5. Health-related quality of life
6. Economic outcomes

Completion date

30/11/2012

Eligibility

Key inclusion criteria

1. Histologic diagnosis of carcinoma of the prostate without evidence of metastatic disease to the lymph nodes, bone or lung; within 6 months of recruitment
2. Intermediate risk prostate cancer, that is:
 - 2.1. T1-2a, Gleason score 6, Prostate Specific Antigen [PSA] 10.1 - 20.0 ng/ml
 - 2.2. T2b-c Gleason 6, PSA less than or equal to 20.0 ng/ml
 - 2.3. T1-2, Gleason 7, PSA less than or equal to 20.0 ng/ml
3. Male prostate cancer patients 50 years old and above

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

Current exclusion criteria as of 12/08/2014:

1. Previous therapy for carcinoma of the prostate other than biopsy or transurethral resection
2. Patients previously on more than 12 weeks of hormone therapy for treatment of their prostate cancer to be excluded from study
3. Any other active malignancy (untreated, progressive or recurrent), except for non-melanoma skin cancer. Any inactive malignancy diagnosed within 5 years of study entry, except for non-melanoma skin cancer.

4. Treatment plan cannot meet dose constraints for the hypofractionation arm of the trial
5. Previous pelvic radiotherapy
6. Inflammatory bowel disease

Previous exclusion criteria:

1. Previous therapy for carcinoma of the prostate other than biopsy or transurethral resection
2. Patients previously on more than 12 weeks of hormone therapy for treatment of their prostate cancer to be excluded from study
3. Prior or active malignancy other than non-melanoma skin cancer, or colon or thyroid cancer treated a minimum of five years prior to study entry and presumed cured
4. Treatment plan cannot meet dose constraints for the hypofractionation arm of the trial
5. Previous pelvic radiotherapy
6. Inflammatory bowel disease

Date of first enrolment

01/11/2005

Date of final enrolment

30/11/2012

Locations

Countries of recruitment

Australia

Canada

Study participating centre

Ontario Clinical Oncology Group (OCOG)

Hamilton, Ontario

Canada

L8V 1C3

Sponsor information

Organisation

Ontario Clinical Oncology Group (OCOG) (Canada)

ROR

<https://ror.org/003w29077>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) (ref: MCT-78776)

Alternative Name(s)

Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	10/06/2017		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes